A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK1903 in Patients With Dyslipidemia.
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2015
At a glance
- Drugs MK 1903 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Merck & Co
- 08 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 08 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.